阿苯达唑
二甲双胍
不利影响
药理学
药品
毒性
医学
化疗
包虫病
内科学
胃肠病学
联合疗法
生物
寄生虫寄主
药物治疗
治疗效果
外科
疾病
最大耐受剂量
抗生素
蠕虫病
甲硝唑
寄生虫病
多房棘球绦虫
作者
Julia A. Loos,Magalí Coccimiglio,María Celeste Nicolao,Christian Rodriguez Rodrigues,Andrea C. Cumino
出处
期刊:Parasitology
[Cambridge University Press]
日期:2021-10-20
卷期号:149 (1): 138-144
被引量:22
标识
DOI:10.1017/s0031182021001633
摘要
Alveolar echinococcosis (AE) is a severe disease caused by Echinococcus multilocularis. Its chemotherapeutic treatment is based on benzimidazoles, which are rarely curative and cause several adverse effects. Therefore, it is necessary to develop alternative and safer chemotherapeutic strategies against AE. It has previously been shown that metformin (Met) exhibits considerable in vivo activity on an early-infection model of AE when administered at 50 mg kg−1 day−1 for 8 weeks. Here, the challenge is heightened by a 2-fold increase in parasite inoculum or by starting the treatment 6 weeks post-infection. In both cases, only the combination of Met (100 mg kg−1 day−1) together with a sub-optimal dose of albendazole (ABZ) (5 mg kg−1 day−1) led to a significant reduction in parasite weight compared to the untreated group. Coincidentally, drug combination showed the highest level of damage in E. multilocularis metacestodes. Likewise, Met alone or combined with ABZ led to a decrease in parasite glucose availability, which was evidenced as a lower intracystic glucose concentration. Therefore, the results demonstrate that combination therapy with Met and ABZ offers an alternative to improve the efficacy and reduce the toxicity of the high-dose ABZ monotherapy currently employed.
科研通智能强力驱动
Strongly Powered by AbleSci AI